Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jennifer Bares"'
Autor:
Jennifer Bares, BS, Apphia Wang, MD, Peter Pavlidakey, MD, Diego De Idiaquez Bakula, MD, Boni Elewski, MD
Publikováno v:
JAAD Case Reports, Vol 3, Iss 1, Pp 78-81 (2017)
Externí odkaz:
https://doaj.org/article/2c2966ef98a941a8b6dbfe515db4687b
Autor:
Hee J. Kim, Ester Del Duca, Ana B. Pavel, Giselle K. Singer, Brian J. Abittan, Margot A. Chima, Grace Kimmel, Jennifer Bares, Danielle Baum, Matthew Gagliotti, Jordan Genece, Justin Chu, Mark G. Lebwohl, Emma Guttman-Yassky
Publikováno v:
Archives of Dermatological Research. 315:215-221
Improved repigmentation of generalized vitiligo in skin types IV-VI has been reported in clinical response to combined therapy with apremilast and narrowband (NB)-UVB; however, tissue responses to combined therapy versus NB-UVB monotherapy have not b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3727a6217e7f8ab9c38dfa9cf82d976b
https://doi.org/10.1007/s00403-022-02343-1
https://doi.org/10.1007/s00403-022-02343-1
Autor:
Hee Jin Kim, Grace Kimmel, Jennifer Bares, Soo Jung Kim, Giselle Singer, Alex Yaroshinsky, Margot Chima, Mark Lebwohl, Jerry Bagel
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:524-529
Background: Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe plaque psoriasis. Our prior publication reported significant disease improvement with brodalumab in psoriasis patients who had previous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e3884d555f30857c4e21315e828bcaa
https://doi.org/10.25251/skin.5.5.10
https://doi.org/10.25251/skin.5.5.10
Autor:
Mark Lebwohl, Emma Guttman-Yassky, Giselle Singer, Jason E. Hawkes, Yael Renert-Yuval, Jennifer Bares, Margot Chima, Patricia Gilleaudeau, Sandra Garcet, Ana B. Pavel, James G. Krueger, Mary Sullivan-Whalen
Publikováno v:
Allergy
BACKGROUND Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA. Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84007341959e7315261390e878bc7986
https://doi.org/10.1111/all.15071
https://doi.org/10.1111/all.15071
Autor:
Yael Renert‐Yuval, Ana B. Pavel, Ester Del Duca, Paola Facheris, Angel D. Pagan, Swaroop Bose, Pedro J. Gómez‐Arias, Michael Angelov, Jennifer Bares, Margo Chima, Yeriel D. Estrada, Sandra Garcet, Mark G. Lebwohl, James G. Krueger, Emma Guttman‐Yassky
Publikováno v:
AllergyREFERENCES.
The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway.W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9fd4fbb0b6f0bd2955ccd13434b81e
https://pubmed.ncbi.nlm.nih.gov/36271804
https://pubmed.ncbi.nlm.nih.gov/36271804
Autor:
Yael Renert-Yuval, Joel Correa da Rosa, Sandra Garcet, Ana B. Pavel, Jennifer Bares, Margot Chima, Jason E. Hawkes, Patricia Gilleaudeau, Mary Sullivan-Whalen, Giselle K. Singer, James G. Krueger, Emma Guttman-Yassky
Publikováno v:
The British journal of dermatologyReferences. 187(4)
Summary Background Although alopecia areata (AA) greatly impacts patients’ quality of life (QoL), there is no adequate validation of AA-targeted QoL surveys in clinical trials, hindering sufficient representation of patient-reported outcomes. Objec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327d2906e36936a1e04adc910b9dbe3b
https://pubmed.ncbi.nlm.nih.gov/35656793
https://pubmed.ncbi.nlm.nih.gov/35656793
Autor:
Matthew Gagliotti, Tinley Chen, John K Nia, Christopher J. Yao, Margot Chima, Jordan Genece, Peter W Hashim, Grace Kimmel, H. Kim, Mark Lebwohl, Giselle Singer, Danielle Baum, Jennifer Bares
Publikováno v:
Journal of the American Academy of Dermatology. 82:360-365
Background Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects. Objective To assess the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341742504c0b0ff6da06aca1ad218059
https://doi.org/10.1016/j.jaad.2019.06.1288
https://doi.org/10.1016/j.jaad.2019.06.1288
Autor:
Jennifer Bares, Mark Lebwohl
Publikováno v:
Current Dermatology Reports. 8:1-5
This review highlights the latest data on risankizumab, including efficacy and safety data from recent clinical trials. In multiple phase 3 clinical trials, risankizumab was shown to be safe and efficacious. Risankizumab demonstrated superior efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25da70645d6f35265d04bff738ecc62b
https://doi.org/10.1007/s13671-019-0250-4
https://doi.org/10.1007/s13671-019-0250-4
Autor:
Margot Chima, Christopher J. Yao, Giselle Singer, Soo Jung Kim, Grace Kimmel, Hee Jin Kim, Mark Lebwohl, Jerry Bagel, Jennifer Bares
Publikováno v:
Journal of the American Academy of Dermatology. 81:857-859
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbef1b139823b198cc65d335a6728ea0
https://doi.org/10.1016/j.jaad.2019.05.007
https://doi.org/10.1016/j.jaad.2019.05.007
Publikováno v:
Hospital Pediatrics. 7:149-155
OBJECTIVE: Pain control remains a problem for hospitalized children, with more than half experiencing ongoing pain. Pain in turn negatively affects child quality of life. To clarify the relationship between inpatient pain control and parent and child
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1692985d41c87ef927a3c57dac4b902
https://doi.org/10.1542/hpeds.2016-0142
https://doi.org/10.1542/hpeds.2016-0142